Allogene Therapeutics, Inc. (ALLO) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Allogene Therapeutics reported revenue of $0, down 100.0% from $22,000 the year before. Net income was -$190.9M, or -$0.87 per diluted share. Operating activities generated -$149.2M of cash, leaving -$149.6M of free cash flow. At fiscal year end, Allogene Therapeutics held $415.9M in total assets against $123.4M in total liabilities, including $51.7M of cash and equivalents.
Open the full interactive Allogene Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Allogene Therapeutics Key Stats
| Share Price | $1.29 |
|---|---|
| Market Cap | $424.3M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $1.05 – $3.06 |
| Shares Outstanding | 328.9 million (basic, 2026 Q2) |
Allogene Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $38.5M | $243,000 | $95,000 | $22,000 | $0 |
| Operating Income | -$258.2M | -$255.8M | -$335.4M | -$327.7M | -$273.2M | -$209.3M |
| Pre-Tax Income | -$250.2M | -$257.0M | -$332.6M | -$327.3M | -$257.1M | -$190.9M |
| Income Tax | $0 | $0 | $0 | $0 | $443,000 | $0 |
| Net Income | -$250.2M | -$257.0M | -$332.6M | -$327.3M | -$257.6M | -$190.9M |
| Diluted EPS | -$2.08 | -$1.89 | -$2.32 | -$2.09 | -$1.32 | -$0.87 |
Allogene Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $800,000 | $4.6M |
| Net Income | -$41.4M | -$38.8M | -$42.6M | -$42.7M |
| Diluted EPS | -$0.19 | -$0.18 | -$0.18 | -$0.13 |
Allogene Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $183.4M | $173.3M | $61.9M | $83.2M | $75.2M | $51.7M |
| Current Assets | $845.1M | $471.3M | $528.8M | $459.1M | $303.4M | $257.7M |
| Total Assets | $1.23B | $1.04B | $817.1M | $642.8M | $548.7M | $415.9M |
| Current Liabilities | $94.3M | $48.2M | $54.5M | $37.1M | $35.5M | $32.5M |
| Total Liabilities | $148.2M | $122.2M | $151.2M | $130.6M | $126.5M | $123.4M |
| Shareholders' Equity | $1.08B | $916.4M | $665.9M | $512.2M | $422.2M | $292.5M |
Allogene Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$115.1M | -$184.8M | -$220.5M | -$237.7M | -$200.3M | -$149.2M |
| Cash From Investing | -$505.1M | $163.7M | $106.2M | $163.3M | $75.7M | $95.6M |
| Cash From Financing | $633.6M | $12.0M | $3.0M | $95.7M | $116.7M | $30.2M |
| Free Cash Flow | -$181.1M | -$206.3M | -$225.7M | -$239.2M | -$201.0M | -$149.6M |
Figures from Allogene Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Allogene Therapeutics financials page for every line item.
Allogene Therapeutics Company Profile
| Ticker | ALLO |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | South San Francisco, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001737287 |
Frequently Asked Questions
What was Allogene Therapeutics' revenue in fiscal 2025?
Allogene Therapeutics (ALLO) reported revenue of $0 for fiscal 2025.
What is Allogene Therapeutics' annual revenue history?
Allogene Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $38.5M; 2022: $243,000; 2023: $95,000; 2024: $22,000; 2025: $0.
What was Allogene Therapeutics' net income in fiscal 2025?
Allogene Therapeutics reported net income of -$190.9M for fiscal 2025.
What was Allogene Therapeutics' earnings per share (EPS) in fiscal 2025?
Allogene Therapeutics' diluted EPS was -$0.87 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Allogene Therapeutics generate in fiscal 2025?
Allogene Therapeutics generated -$149.6M of free cash flow in fiscal 2025.
What was Allogene Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Allogene Therapeutics reported revenue of $4.6M.
How many shares of Allogene Therapeutics are outstanding?
Allogene Therapeutics reported a weighted average of 328.9 million basic shares outstanding in 2026 Q2.
What is Allogene Therapeutics' market cap?
Based on its latest closing price, Allogene Therapeutics (ALLO) has a market capitalization of about $424.3M.
When does Allogene Therapeutics' fiscal year end?
Allogene Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Allogene Therapeutics headquartered?
Allogene Therapeutics lists its business address in South San Francisco, California in its SEC filings.
Allogene Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →